Opinion|Videos|May 21, 2025
CABINET Trial: Results
Author(s)Thorvardur R. Halfdanarson, MD
A panelist discusses how the CABINET trial showed significant progression-free survival benefits for cabozantinib compared with placebo (particularly in pancreatic neuroendocrine tumors (NETs), why progression-free survival (PFS) is a meaningful end point for NETs, and that safety findings revealed familiar adverse effects requiring dose reductions in about two-thirds of patients.
Advertisement
Video content above is prompted by the following:
CABINET Trial Results
Key Themes:
- Progression-Free Survival (PFS) as Primary End Point:
- PFS is an agreed-upon end point by an NCI task force for NETs
- Appropriate due to generally longer overall survival in NETs compared with other metastatic solid tumors
- PFS serves as a surrogate for benefit and possibly overall survival
- Extrapancreatic Cohort Results:
- PFS: 8.4 months (cabozantinib) vs 3.9 months (placebo); statistically significant
- Overall survival: 21.9 months vs 19.7 months; not statistically significant
- 33% crossed over from placebo to cabozantinib
- Pancreatic Cohort Results:
- PFS: 13.8 months (cabozantinib) vs 4.4 months (placebo); more pronounced difference
- Overall survival: 40 months vs 31.1 months; not statistically significant
- 41% crossed over from placebo to cabozantinib
- Safety Profile:
- No new safety signals identified
- Two-thirds of patients required dose reduction
- Average daily dose was just under 40 mg per day in both cohorts
Notable Insights:
Dr Halfdanarson observed that the more pronounced PFS benefit in pancreatic NETs was not surprising, as these tumors have historically been responsive to VEGF-directed therapies like sunitinib.
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5